Subscribe To
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating pyrukynd® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating pyrukynd® in Adults with Non...
December 10, 2022, 11:30 pm
Agios pharmaceuticals is a buy on coming revenue ramp
Agios sold its first successful commercial drug to Servier for $2 billion. Launch of second drug, pyrukynd...
July 26, 2022, 12:32 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) pyrukynd (mitapivat) for hemolytic anemi...
February 18, 2022, 5:41 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) pyrukynd (mitapivat) for hemolytic anemi...
February 18, 2022, 5:41 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) pyrukynd (mitapivat) for hemolytic anemi...
February 18, 2022, 5:41 am